

Sartorius Group – Conference Call Nine-Month Figures for 2009

Joachim Kreuzburg, CEO

Goettingen, October 22, 2009


Disclaimer



This presentation contains statements concerning the Sartorius and Sartorius Stedim Biotech Groups' future performance. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

Order Intake by Division



Currency-Adjusted Growth:

- Group: -2.3%
- Biotechnology Division: +10.3%
- Mechatronics Division: -20.6%

Biotechnology Division:


- Strong double-digit growth of single-use products
- Additional momentum generated by the vaccine industry because of the pandemic flu (approx. +2% points additional sales and overproportionate profit contribution in 2009)

Mechatronics Division:

- Since Q4 | 2008 sharp cyclically drop in demand worldwide
- Stabilization since Q2

Order Intake by Quarter - Biotechnology

Currency-adjusted*




- Continuous double-digit gains of high-margin single-use products
- All regions contributed to order intake growth; double-digit increase in North America and Asia
- Growth impulse in the equipment business in Q3

* based on budget rates 2008

** pro forma

Order Intake by Quarter - Mechatronics

Currency-adjusted*




* based on budget rates 2008

- Since November 2008, significant decline in order intake worldwide
- Order situation stabilized since Q2 | 2009
- Slump in demand particularly from customers in the chemical sector
- Since Q2 | 2009, especially the industrial business is heavily impacted

Sales by Division

€ in mn




Currency-Adjusted Growth:

- Group: -4.3%
- Biotechnology Division: +6.7%
- Mechatronics Division: -21.1%

Sales Revenue by Region – Biotechnology

According to customers' location

€ in mn




Currency-Adjusted Growth:

- Europe: +4.2%
- North America: +9.6%
- Asia | Pacific: +6.2%
- All regions contributed to the growth
- Especially in North America, the Group grew significantly yet again

Sales Revenue by Region – Mechatronics

According to customers' location

€ in mn




Currency-Adjusted Growth:

- Europe: -23.7%
- North America: -20.0%
- Asia | Pacific: -14.0%
- Highest slump in demand in Europe
- Asia | Pacific slightly less affected

Underlying EBITA*

€ in mn



* Excluding extraordinary expenses

Underlying EBITA Margin*:

Biotechnology: 15.5% (prev. year: 10.7%)

- Economies of scale and an improved product mix contributed to the increase in profit

Mechatronics: -1.6% (prev. year: 6.3%)


- Cost-cutting measures are showing effect
- After two quarters with losses, slightly positive underlying EBITA in Q3

Group: 9.9% (prev. year: 8.9%)

- Extraordinary expenses of €24.7mn essentially entail provisions for the restructuring in the Mechatronics Division

Underlying Earnings per Share*

in €



- Slight increase of underlying EPS*
- Underlying net profit after minority interest* totaled €13.9mn (prev. year: €13.7mn)

* Excluding extraordinary expenses, and the two non-cash items amortization and interest expenses for share price warrants

Cash Flow Statement

In millions of €

	9-month 2009	9-month 2008
Net cash flow from operating activities	104.8	15.3
Net cash flow from investing activities	-123.7	-22.3
Change in net debt* (- means a decrease; + means an increase)	+36.3	+30.9

- Increase of net cash flow from operating activities driven by factoring (€36.0mn) and significant optimization of working capital (€15.9mn).
- Cash flow from investing activities includes warrant payment of €103.7mn.

* compared to December 31 of the previous year

Balance Sheet as of September 30, 2009

Assets			Equity and liabilities		
Non-current assets	€591.1mn	71.0%	Equity	€319.3mn	38.3%
Current assets	€241.9mn	29.0%	Financial debt	€304.8mn	36.6%
			Non-financial debt	€209.0mn	25.1%
Total	€833.1mn	100%	Total	€833.1mn	100%

- Gearing: 0.8
- Ratio of net debt to underlying EBITDA: 3.0
- Interest coverage: 7.0
- No adjustments to the company's syndicated loan agreement were necessary.

Restructuring Program in the Mechatronics Division



Cost-Cutting Program Extended

- Cost reduction of more than €30mn p.a. targeted (thereof more than €25mn p.a. of personnel costs)
- Nine-month results include almost all extraordinary expenses that can be expected in this context
- Goal: Mechatronics Division to swing back to profit in 2010

Shift from Technology to Application Orientation

- Focus on food & pharma
- Utilization of synergies between the two divisions
- Addressing key industrial trends
- Increase share of direct sales vs. distribution
- Broaden product portfolio through cooperations

Outlook

- For the last three months of the current fiscal year, company management expects the Biotechnology Division's revenue to increase and its earnings to rise overproportionately relative to the fourth quarter in 2008.
- The company continues to expect exceptionally difficult market conditions for the Mechatronics Division. However, management anticipates a slightly positive fourth-quarter underlying EBITA for this division because of its successfully implemented cost-reduction program.




Sartorius Stedim Biotech Group – Conference Call Nine-Month Figures for 2009

Joachim Kreuzburg, CEO

Goettingen, October 22, 2009

Order Intake and Sales Revenue




- Increase driven by strong double-digit growth rates of single-use products
- Added growth momentum for high-margin single-use products due to global expansion of swine flu vaccine production
- Through this, approx. 2% points of additional sales and overproportionate profit contribution expected for full year 2009

Currency-Adjusted Growth:

- Order intake: 9.9%
- Sales : 6.3%

Order Intake by Quarter

Currency-adjusted*



* based on budget rates 2008


** pro forma

- Continuous double-digit gains of high-margin single-use products
- All regions contributed to order intake growth; double-digit increase in North America and Asia
- Growth impulse in the equipment business in Q3

Sales Revenue by Region

According to customers' location

€ in mn




Currency-Adjusted Growth:

- Europe: +4.0%
- North America: +9.6%
- Asia | Pacific: +4.8%
- All regions contributed to the growth
- Especially in North America, the Group grew significantly yet again

Underlying EBITA*

€ in mn




- Underlying EBITA margin* significantly increased to 15.5% (prev. year: 10.8%)
- Economies of scale and an improved product mix contributed to the increase in profit
- Underlying adjustments of €1.8mn mainly consist of non-operating depreciation

* Excluding extraordinary expenses

Underlying Earnings per Share*

in €



- Overproportionate increase of underlying EPS*
- Underlying net profit after minority interest* totaled €26.5mn (prev. year: €13.9mn)

* Excluding extraordinary expenses, and the non-cash item amortization

Cash Flow Statement

In millions of €

	9-month 2009	9-month 2008
Net cash flow from operating activities	65.5	35.9
Net cash flow from investing activities	-11.0	-13.1
Change in net debt* (- means a decrease; + means an increase)	-43.7	-11.1

* compared to December 31 of the previous year

Balance Sheet as of September 30, 2009

Assets			Equity and liabilities		
Non-current assets	€481.4mn	71.0%	Equity	€387.4mn	57.1%
Current assets	€197.0mn	29.0%	Financial debt	€162.9mn	24.0%
			Non-financial debt	€127.9mn	18.9%
Total	€678.3mn	100%	Total	€678.3mn	100%

- Gearing: 0.3
- Ratio of net debt to underlying EBITDA: 1.5
- Interest coverage: 9.5

Outlook

- For the last three months of the current fiscal year, company management expects the revenue to increase and earnings to rise overproportionately relative to the fourth quarter in 2008.



Thank you very much for your attention.

Joachim Kreuzburg, CEO

Goettingen, October 22, 2009